JO
MREO

John Overdeck’s Mereo BioPharma MREO Stock Holding History

John Overdeck’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419K Buy
1,319,241
+1,131,402
+602% +$339K ﹤0.01% 4286
2026
Q1 		$62K Sell
187,839
-337,286
-64% -$145K ﹤0.01% 4436
2025
Q4 		$219K Sell
525,125
-562,971
-52% -$1.07M ﹤0.01% 3734
2025
Q3 		$2.24M Buy
1,088,096
+428,938
+65% +$791K ﹤0.01% 2047
2025
Q2 		$1.79M Buy
659,158
+413,952
+169% +$999K ﹤0.01% 1923
2025
Q1 		$552K Buy
245,206
+176,471
+257% +$499K ﹤0.01% 2484
2024
Q4 		$241K Sell
68,735
-65,578
-49% -$258K ﹤0.01% 2813
2024
Q3 		$552K Sell
134,313
-67,463
-33% -$279K ﹤0.01% 2422
2024
Q2 		$726K Sell
201,776
-149,953
-43% -$486K ﹤0.01% 2169
2024
Q1 		$1.16M Buy
351,729
+40,669
+13% +$138K ﹤0.01% 1860
2023
Q4 		$719K Buy
311,060
+168,458
+118% +$322K ﹤0.01% 2266
2023
Q3 		$184K Sell
142,602
-55,157
-28% -$73.2K ﹤0.01% 2654
2023
Q2 		$261K Buy
+197,759
New +$229K ﹤0.01% 2557

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM

John Overdeck's MREO Position: Q2 2026 in Review

John Overdeck increased its Mereo BioPharma (MREO) stake by 602% in Q2 2026, buying an estimated $339K and bringing the position to 1,319,241 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #4286.

John Overdeck first reported a position in MREO in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.24M in Q3 2025. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • John Overdeck held 1,319,241 shares of Mereo BioPharma worth $419K as of Q2 2026.
  • John Overdeck bought 1,131,402 Mereo BioPharma shares in Q2 2026, an estimated $339K.
  • Mereo BioPharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4286 holding.
  • John Overdeck first reported a position in Mereo BioPharma in Q2 2023 and has held it in 13 quarters since.
  • John Overdeck's Mereo BioPharma position peaked at $2.24M in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.